Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

LEXINGTON For the past four decades, the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) has been at the ...

For the past four decades, the University of Kentucky’s Sanders-Brown Center on Aging has been at the forefront of Alzheimer’s disease research, making groundbreaking discoveries that have shaped expe ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

Royal Melbourne Hospital (RMH) is one of more than a dozen sites around Australia taking part in the major global trial for ...

This groundbreaking research reveals that subtle chemical changes in tau may quietly set off a chain reaction, spreading ...

An estimated 7.2 million Americans aged 65 years and older are living with Alzheimer dementia, and almost all adults feel it is important to diagnose the disease in the early stages.

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

Four South Florida sites are enrolling people with memory loss into a national trial for benfotiamine, a lab-made vitamin ...